Aly-Khan Lalani - McMaster Experts

Affiliations

Faculty of Health Sciences, McMaster University
Full-Time Member, Escarpment Cancer Research Institute (ECRI), Faculty of Health Sciences
Associate Professor, Oncology, Faculty of Health Sciences
Staff Medical Oncologist, Juravinski Cancer Centre,
Chair, Genitourinary Cancers Disease Site Team, Juravinski Cancer Centre,

Research Areas

Cancer (RA)
Cancer drug development and therapeutics (RA)
Microbiome (RA)

Scholarly Activity in McMaster Experts

Co-author Network

Scholarly Activity
Contact
View All

selected scholarly activity

conferences
- Association of cabozantinib dose reductions for toxicity with clinical effectiveness in metastatic renal cell carcinoma: Results from the Canadian Kidney Cancer Information System (CKCis. Clinical Genitourinary Cancer. 102060-102060. 2024
- Efficacy of post-lenvatinib treatments in patients (pts) with advanced renal cell carcinoma (aRCC). Journal of Clinical Oncology. 2024
- Practice patterns of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in real-world Canadian practice.. Journal of Clinical Oncology. 2024
- Real-world treatment practices in patients with muscle invasive bladder cancer (MIBC) treated in Alberta, Canada.. Journal of Clinical Oncology. 2024
- Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC). Journal of Clinical Oncology. 2024
- ASSOCIATION BETWEEN THE SARCOMATOID STATUS AND PERCENTAGE OF SARCOMATOID ON THE CLINICAL OUTCOMES OF LOCALIZED RENAL CELL CARCINOMA POST NEPHRECTOMY. Journal of Urology. E597-E597. 2024
- Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology. 488-492. 2024
- Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy.. Journal of Clinical Oncology. 2023
- IS A RENAL TUMOUR BENIGN OR MALIGNANT? A PREDICTION TOOL INCLUDING PATIENTS MANAGED WITH SURGERY, ABLATION, OR SURVEILLANCE. Journal of Urology. E555-E555. 2023
- OUTCOMES OF PARTIAL NEPHRECTOMY FOR NON-METASTATIC CT2 RENAL TUMORS: RESULTS FROM A CANADIAN MULTI-INSTITUTIONAL COLLABORATIVE. Journal of Urology. E166-E166. 2023
- Patients from Institutions with a Low pT2 Call Rate in Clear Cell Renal Cell Carcinoma may Experience Lower Stage-Specific Recurrence and Death. Laboratory Investigation. S1698-S1699. 2023
- ASSOCIATION BETWEEN THE SARCOMATOID STATUS AND PERCENTAGE OF SARCOMATOID ON THE CLINICAL OUTCOMES OF LOCALIZED RENAL CELL CARCINOMA POST NEPHRECTOMY. Value in Health. S52-S52. 2022
- CLINICAL OUTCOMES OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) WITH OR WITHOUT SARCOMATOID DIFFERENTIATION TREATED WITH SYSTEMIC THERAPY IN REAL-WORLD CANADIAN SETTING. Value in Health. S39-S39. 2022
- The impact of impaired renal function on the effectiveness of first-line immuno-oncology combination therapies in metastatic renal cell carcinoma (mRCC): Results from the international metastatic RCC database consortium (IMDC). Annals of Oncology. S660-S680. 2022
- 1464P The impact of impaired renal function on the effectiveness of first-line immuno-oncology combination therapies in metastatic renal cell carcinoma (mRCC): Results from the international metastatic RCC database consortium (IMDC). Annals of Oncology. S1215-S1216. 2022
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 1133-1144. 2022
- Significant variation of tumour stage by size in clear cell renal cell carcinoma from a prospective national database with a sub-analysis for causality. Virchows Archiv. S351-S352. 2022
- OUTCOMES OF PARTIAL NEPHRECTOMY FOR NON-METASTATIC CT2 RENAL TUMORS: RESULTS FROM A CANADIAN MULTI-INSTITUTIONAL COLLABORATIVE. Journal of Urology. E394-E394. 2022
- Association of cabozantinib dose reductions for toxicity with clinical effectiveness in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. Journal of Clinical Oncology. 316-316. 2022
- Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).. Journal of Clinical Oncology. 304-304. 2022
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. Journal of Clinical Oncology. TPS398-TPS398. 2022
- Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma.. Journal of Clinical Oncology. 2022
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). Journal of Clinical Oncology. 2022
- Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Advances in Radiation Oncology. 2022
- PD40-07 CLINICAL OUTCOMES AND ADVERSE EVENTS AFTER FIRST-LINE TREATMENT IN METASTATIC RENAL CELL CARCINOMA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS. Investigative Urology. e676-e677. 2021
- Real-Word Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). Kidney Cancer. 21-29. 2021
- Outcomes of Radiotherapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From The Canadian Kidney Cancer Information System (CKCis). International Journal of Radiation Oncology Biology Physics. e887-e887. 2020
- Sites of metastasis and survival in metastatic renal-cell carcinoma (mRCC): Resuits from the international mRCC Database Consortium (IMDC). Asia-Pacific Journal of Clinical Oncology. 4-4. 2020
- Abstract NG13: Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Cancer Research. NG13-NG13. 2020
- Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Journal of Clinical Oncology. 2020
- Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology. 639-639. 2020
- Impact of early identification of brain metastases in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 2020
- Impact of early identification of brain metastases in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 620-620. 2020
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). Journal of Clinical Oncology. 2020
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. Journal of Clinical Oncology. TPS761-TPS761. 2020
- Real-world evidence of cabozantinib in metastatic renal-cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis). Journal of Clinical Oncology. 2020
- Real-world utilization and safety of ipilimumab plus nivolumab (I plus N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis). Journal of Clinical Oncology. 2020
- Real-world utilization and safety of ipilimumab plus nivolumab (I+N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).. Journal of Clinical Oncology. 633-633. 2020
- Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Journal of Clinical Oncology. 2020
- Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology. 642-642. 2020
- CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. 885-885. 2019
- CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. v885-v885. 2019
- Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in advanced renal cell carcinoma (RCC). Annals of Oncology. 396-396. 2019
- Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in advanced renal cell carcinoma (RCC). Annals of Oncology. v396-v396. 2019
- Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. Journal of Clinical Oncology. 4516-4516. 2019
- Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. Journal of Clinical Oncology. 568-568. 2019
- Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 566-566. 2019
- Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC). Annals of Oncology. viii311-viii311. 2018
- CD73 expression in primary and metastatic renal cell carcinoma (RCC).. Journal of Clinical Oncology. 643-643. 2018
- Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology. 626-626. 2018
- Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.. Journal of Clinical Oncology. 667-667. 2018
- Renal cell carcinoma (RCC) primary tumor shrinkage on vascular endothelial growth factor (VEGF)-targeted therapy (TT): A pooled analysis.. Journal of Clinical Oncology. 629-629. 2018
- Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. Journal of Clinical Oncology. e16065-e16065. 2017
- Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. Journal of Clinical Oncology. e16078-e16078. 2017
- Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. Journal of Clinical Oncology. 468-468. 2017
- Proton-pump inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. BJU International. 7-7. 2016
- Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience. Annals of Oncology. vi285-vi285. 2016
- Abstract P3-07-13: Outcomes of women with small, early-stage breast cancer in Manitoba from 1995-2011. Cancer Research. p3-07-13-p3-07-13. 2015
- Outcomes of women with small, early-stage breast cancer in Manitoba from 1995-2011. Cancer Research. 2015
- Optimizing the travel experiences of children and families during flight.. Journal of Investigative Medicine. S173-S173. 2006
journal articles
- Adjuvant pembrolizumab following kidney cancer surgery A novel patient decision aid to facilitate shared decision-making.. Journal of the Canadian Urological Association. 19:205-207. 2025
- Assessment of time-to-treatment-failure (TTF) as a surrogate endpoint for overall survival (OS) to immune checkpoint inhibitor (ICI) regimens in metastatic renal cell carcinoma (mRCC): Findings from an IMDC analysis.. Journal of Clinical Oncology. 43:4528-4528. 2025
- Canadian Cancer Trials Group (CCTG) IND.234/223: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)–A molecularly selected cooperative group platform study.. Journal of Clinical Oncology. 43:5066-5066. 2025
- Clinical outcomes of patients with primary refractory metastatic renal cell carcinoma receiving second-line (2L) therapies: An International Metastatic Database Consortium (IMDC) study.. Journal of Clinical Oncology. 43:4555-4555. 2025
- Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care.. Journal of Clinical Oncology. 43. 2025
- Optimal Timing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Considering Sarcomatoid Status: A Real-World Study.. Clinical Genitourinary Cancer. 23:102342. 2025
- Second-line outcomes in metastatic renal cell carcinoma: The role of International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic factors after first-line immunotherapy.. Journal of Clinical Oncology. 43:4548-4548. 2025
- Substudy C of the Canadian cancer trials group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A phase II study of darolutamide (DARO) selected by androgen-receptor (AR) circulating tumor DNA (ctDNA) in patients (PTS) with metastatic castration-resistant prostate cancer (mCRPC) after prior AR pathway inhibitors (ARPIs).. Journal of Clinical Oncology. 43:5056-5056. 2025
- Substudy G of the Canadian cancer trials group (CCTG) IND.234: PC_BETS (V)—A circulating tumor DNA (ctDNA)–directed phase II study of carboplatin in patients (Pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 43:5058-5058. 2025
- A COST-UTILITY ANALYSIS OF ENFORTUMAB VEDOTIN AND PEMBROLIZUMAB VERSUS NIVOLUMAB PLUS GEMCITABINE-CISPLATIN IN ADVANCED UROTHELIAL CARCINOMA. Investigative Urology. 213. 2025
- Is there a minimum percentage of sarcomatoid component required to affect outcomes of localised renal cell carcinoma?. BJU International. 135:818-827. 2025
- MP02-05 MULTI-INSTITUTIONAL VALIDATION STUDY OF THE KIDNEY CANCER RISK EQUATION (KCRE): RESULTS FROM THE CANADIAN KIDNEY CANCER INFORMATION SYSTEM (CKCis). Investigative Urology. 213:e13. 2025
- MP02-06 DOES RADICAL NEPHRECTOMY FOR HIGH-GRADE RENAL CELL CARCINOMA IMPROVE OUTCOMES COMPARED TO PARTIAL NEPHRECTOMY? RESULTS FROM a CANADIAN MULTICENTRE COHORT. Investigative Urology. 213:e13. 2025
- MP14-16 UPFRONT CYTOREDUCTIVE NEPHRECTOMY WITH DEFERRED SYSTEMIC THERAPY FOR METASTATIC RENAL CELL CARCINOMA. Investigative Urology. 213:e492. 2025
- RADIANT: A window of opportunity trial exploring preoperative immunomodulatory radiotherapy and durvalumab prior to radical cystectomy in patients with cisplatin-ineligible muscle-invasive bladder carcinoma Free. Cancer Research. 85. 2025
- Validation of Prognostic Models for Renal Cell Carcinoma Recurrence, Cancer-Specific Mortality, and All-Cause Mortality.. Investigative Urology. 213:455-466. 2025
- Adjuvant immunotherapy in high-risk muscle invasive urothelial carcinoma: A systematic review and meta-analysis of randomized clinical trials.. Urologic Oncology: Seminars and Original Investigations. 43:156-163. 2025
- METABOLIC, CARDIAC, AND BONE HEALTH TESTING IN PROSTATE CANCER PATIENTS ON ANDROGEN DEPRIVATION THERAPY: A POPULATION-BASED ASSESSMENT OF ADHERENCE TO THERAPEUTIC MONITORING GUIDELINES. Urologic Oncology: Seminars and Original Investigations. 43. 2025
- Association between abnormal IMDC laboratory criteria after surgery and cancer-specific and overall survival in non-metastatic renal cell carcinoma: Potential biomarkers for adjuvant therapy patient selection.. Journal of Clinical Oncology. 43. 2025
- Association between sociodemographic marginalization and receipt of intensified treatment for metastatic castrate-sensitive prostate cancer.. Journal of Clinical Oncology. 43. 2025
- Bone metastases and use of bone protective agents (BPA) for metastatic renal cell carcinoma (mRCC): A contemporary national real-world analysis.. Journal of Clinical Oncology. 43. 2025
- Cabozantinib real-world effectiveness in the second-line setting of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology. 43. 2025
- Concomitant G-CSF use in maintaining an efficacious dose and safe delivery of docetaxel in combination with darolutamide in patients with metastatic hormone sensitive prostate cancer (mHSPC): ARASENS, a phase 3 study.. Journal of Clinical Oncology. 43. 2025
- Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma.. Journal of Clinical Oncology. 43. 2025
- Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status Patients.. Cancers. 17:522. 2025
- Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis.. European urology oncology. 8:171-178. 2025
- Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer.. Clinical Cancer Research. 31:45-55. 2025
- Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen-deprivation therapy: A population-based assessment of adherence to therapeutic monitoring guidelines.. Cancer. 131:e35606. 2025
- Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma. European Urology Focus. S2405-4569(24)00257-8. 2024
- 2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma.. Journal of the Canadian Urological Association. 18:E371-E386. 2024
- Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database.. Current Oncology. 31:4704-4712. 2024
- 20 Evaluating intermediate endpoints for overall survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors: an IMDC study. Oncologist. 29:S8-S9. 2024
- 35 Efficacy of treatments post-lenvatinib in patients with advanced renal cell carcinoma (aRCC). Oncologist. 29:S22-S22. 2024
- Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens. Oncologist. 29:699-706. 2024
- Real-World Outcomes in Patients with Advanced/Metastatic Renal Cell Carcinoma Receiving Cabozantinib or Other Tyrosine Kinase Inhibitors After Checkpoint Inhibitor-Based Therapy. Kidney Cancer. 8:99-114. 2024
- 20 Evaluating intermediate endpoints for overall survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors: an IMDC study. Oncologist. 29:S8-S9. 2024
- 35 Efficacy of treatments post-lenvatinib in patients with advanced renal cell carcinoma (aRCC). Oncologist. 29:S22-S22. 2024
- Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study. European Urology. 86:4-9. 2024
- Efficacy of post-lenvatinib treatments in patients (pts) with advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology. 42:4538-4538. 2024
- Practice patterns of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in real-world Canadian practice.. Journal of Clinical Oncology. 42:e16594-e16594. 2024
- Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies. European urology oncology. 7:570-580. 2024
- Real-world treatment practices in patients with muscle invasive bladder cancer (MIBC) treated in Alberta, Canada.. Journal of Clinical Oncology. 42:e16596-e16596. 2024
- Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology. 42:4514-4514. 2024
- Percées dans la prise en charge de l’hypernéphrome. CANADIAN MEDICAL ASSOCIATION JOURNAL. 196:E601-E607. 2024
- MP36-13 ASSOCIATION BETWEEN THE SARCOMATOID STATUS AND PERCENTAGE OF SARCOMATOID ON THE CLINICAL OUTCOMES OF LOCALIZED RENAL CELL CARCINOMA POST NEPHRECTOMY. Investigative Urology. 211:e597. 2024
- Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. Journal of Clinical Oncology. 42:1222-1228. 2024
- Addressing controversial areas in the management of advanced prostate cancer in Canada. Journal of the Canadian Urological Association. 18:E127-E137. 2024
- Advances in the management of renal cell carcinoma. CANADIAN MEDICAL ASSOCIATION JOURNAL. 196:E235-E240. 2024
- Impact of timing of immunotherapy and cytoreductive nephrectomy on outcomes in metastatic renal cell carcinoma: Results from the CKCis database.. Journal of Clinical Oncology. 42:416-416. 2024
- Ipilimumab/nivolumab (I/N) compared to axitinib/pembrolizumab (A/P) in metastatic renal cell carcinoma (mRCC): Insights from a Canadian population.. Journal of Clinical Oncology. 42:393-393. 2024
- Management, outcomes and predictors of recurrence in chromophobe renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).. Journal of Clinical Oncology. 42:389-389. 2024
- Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.. Journal of Clinical Oncology. 42:367-367. 2024
- Real-world practice patterns, treatment-related toxicity, and survival outcomes in older patients with metastatic renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).. Journal of Clinical Oncology. 42:366-366. 2024
- Real-world treatment outcomes in patients with advanced renal cell carcinoma who receive axitinib plus pembrolizumab in the first-line setting in Canadian cancer centers.. Journal of Clinical Oncology. 42:382-382. 2024
- Treatment-free survival after first-line therapies for metastatic renal cell carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis.. Journal of Clinical Oncology. 42:390-390. 2024
- 1893P Immune-related adverse events from contemporary first-line combination therapies in metastatic renal cell carcinoma: Results from the IMDC. Annals of Oncology. 34:S1018-S1019. 2023
- Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma. Hematology/Oncology Clinics of North America. 37:937-942. 2023
- Erratum: 2023 CKCF consensus statement. Journal of the Canadian Urological Association. 17:E337-E337. 2023
- Optimizing Treatment Selection in Advanced Renal Cell Carcinoma via IMDC Risk Group Stratification. European Urology. 84:379-380. 2023
- Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System. Journal of Global Oncology. 9:e2300271. 2023
- How I Do It: Maintenance avelumab for advanced urothelial carcinoma.. Canadian Journal of Urology. 30:11633-11638. 2023
- Comparison of patients with renal cell carcinoma in adjuvant therapy trials to a real-world population. Urologic Oncology: Seminars and Original Investigations. 41:328.e15-328.e23. 2023
- Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. European Urology. 84:109-116. 2023
- Corrigendum to “Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma” [Eur Urol 2023]. European Urology. 83:e166-e167. 2023
- Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy.. Journal of Clinical Oncology. 41:4530-4530. 2023
- Adjuvant therapy for renal cell carcinoma. Journal of the Canadian Urological Association. 17:E154-63. 2023
- MP41-03 IS A RENAL TUMOUR BENIGN OR MALIGNANT? A PREDICTION TOOL INCLUDING PATIENTS MANAGED WITH SURGERY, ABLATION, OR SURVEILLANCE. Investigative Urology. 209:e555. 2023
- PD07-10 OUTCOMES OF PARTIAL NEPHRECTOMY FOR NON-METASTATIC cT2 RENAL TUMORS: RESULTS FROM A CANADIAN MULTI-INSTITUTIONAL COLLABORATIVE. Investigative Urology. 209:e166. 2023
- Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma. Cancer Reports. 6:e1763. 2023
- Outcomes of partial nephrectomy for non-metastatic cT2 renal tumors: Results from a Canadian multi-institutional collaborative.. Journal of Clinical Oncology. 41:690-690. 2023
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. Journal of Clinical Oncology. 41:TPS750-TPS750. 2023
- The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma. Human Vaccines and Immunotherapeutics. 19:2178217. 2023
- CO107 Clinical Outcomes of Patients With Metastatic Renal Cell Carcinoma (MRCC) With or Without Sarcomatoid Differentiation Treated With Systemic Therapy in Real-World Canadian Setting. Value in Health. 25:S39-S39. 2022
- CO177 Association Between the Sarcomatoid Status and Percentage of Sarcomatoid on the Clinical Outcomes of Localized Renal Cell Carcinoma Post Nephrectomy. Value in Health. 25:S52-S52. 2022
- Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma. Current Oncology. 29:5426-5441. 2022
- Emerging Biomarker-Guided Therapies in Prostate Cancer. Current Oncology. 29:5054-5076. 2022
- Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Advances in Radiation Oncology. 7:100899-100899. 2022
- Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review. Therapeutic Advances in Medical Oncology. 14:175883592211086-175883592211086. 2022
- Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. Clinical Genitourinary Cancer. 20:210-218. 2022
- Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. Clinical Cancer Research. 28:738-747. 2022
- The perceptions and beliefs of cannabis use among Canadian genitourinary cancer patients. Journal of the Canadian Urological Association. 16:48-54. 2022
- Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. Investigative Urology. 207:16-24. 2022
- Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. Journal for ImmunoTherapy of Cancer. 10:e003024-e003024. 2022
- Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Clinical Genitourinary Cancer. 19:521-530. 2021
- The emerging treatment landscape of advanced urothelial carcinoma. Current opinion in supportive and palliative care. 15:247-252. 2021
- Canadian consensus forum of key controversial areas in the management of advanced prostate cancer. Journal of the Canadian Urological Association. 15:353-358. 2021
- Cytoreductive stereotactic body radiotherapy (SBRT) and combination SBRT with immune checkpoint inhibitors (ICIs) in metastatic renal cell carcinoma. Journal of the Canadian Urological Association. 15:281-286. 2021
- Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma. JAMA Oncology. 7:773-773. 2021
- Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. Journal of the Canadian Urological Association. 15:84-97. 2021
- Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer Medicine. 10:1212-1221. 2021
- Genomic and Clinical Correlates of Adrenocortical Carcinoma in an Adult Patient with Li-Fraumeni Syndrome: A Case Report. Current Oncology. 28:226-232. 2020
- Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts. Journal of Global Oncology. 6:293-306. 2020
- Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. European urology oncology. 3:695-699. 2020
- 211: Outcomes of Radiotherapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results from the Canadian Kidney Cancer Information System (CKCIS). Radiotherapy and Oncology. 150:S89-S90. 2020
- Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. European Journal of Cancer. 135:203-210. 2020
- Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Kidney Cancer. 4:119-119. 2020
- Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. European urology oncology. 3:372-381. 2020
- Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic. Journal of the Canadian Urological Association. 14:E154-E158. 2020
- Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer. Journal of the Canadian Urological Association. 14:123-130. 2020
- Controversial issues in the management of patients with advanced prostate cancer: Results from a Canadian consensus forum. Journal of the Canadian Urological Association. 14:E137-E149. 2020
- Continuing towards optimization of bladder cancer care in Canada: Summary of the 3rd Bladder Cancer Canada-Canadian Urological Association- Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. Journal of the Canadian Urological Association. 14:E115-E125. 2020
- Real-world evidence of cabozantinib in metastatic renal-cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. Journal of Clinical Oncology. 38:682-682. 2020
- From Famine to Feast: Treating Urinary Malignancies in the Immunotherapy Era. European Urology Focus. 6:1-2. 2020
- State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. European Urology Focus. 6:37-40. 2020
- Response of Primary Renal Cell Carcinoma to Systemic Therapy. European Urology. 76:852-860. 2019
- Capturing recurrence in urothelial carcinoma: “more than meets the eye”. Translational Andrology and Urology. 8:S524-S527. 2019
- Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. Journal of the Canadian Urological Association. 13:343-54. 2019
- Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nature Communications. 10:4346. 2019
- Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. Journal of the Canadian Urological Association. 13:166-174. 2019
- Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. European Urology. 75:100-110. 2019
- Systemic treatments for metastatic urothelial carcinoma. Expert Opinion on Pharmacotherapy. 20:201-208. 2019
- Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 6:5. 2018
- Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. British Journal of Cancer. 119:707-712. 2018
- The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma. Cancer immunology research. 6:758-765. 2018
- Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). British Journal of Cancer. 118:1434-1441. 2018
- Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. British Journal of Cancer. 118:1238-1242. 2018
- Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. Cancer immunology research. 6:402-408. 2018
- Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)1. Kidney Cancer. 2:31-36. 2018
- Antibiotic use and outcomes with systemic therapy in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 36:607-607. 2018
- JAVELIN: avelumab another spear to fight urothelial carcinoma. The Lancet Oncology. 19:5-7. 2018
- Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 15:724-732. 2017
- Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. Journal for ImmunoTherapy of Cancer. 5:66. 2017
- Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non–Lymph Node Distant Metastasis. Clinical Genitourinary Cancer. 15:e1089-e1094. 2017
- Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. Oncotarget. 8:103428-103436. 2017
- Immunotherapy in the Elderly. European Urology Focus. 3:403-412. 2017
- Change in neutrophil-to-lymphocyte ratio (NLR) in response to immunotherapy for metastatic renal cell carcinoma (mRCC). Annals of Oncology. 28:v314-v315. 2017
- Pan-urologic cancer genomic subtypes that transcend tissue of origin. Nature Communications. 8:199. 2017
- Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression.. Journal of Clinical Oncology. 35:4573-4573. 2017
- Outcomes of women with small, early-stage breast cancer in Manitoba from 2006-2011.. Journal of Clinical Oncology. 35:e12000-e12000. 2017
- Proton pump inhibitors (PPIs) and survival outcomes in patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 35:493-493. 2017
- First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. Journal of the Canadian Urological Association. 11:112-112. 2017
- Manifestations of Von Hippel Lindau syndrome: a retrospective national review. QJM - Monthly Journal of the Association of Physicians. 107:291-296. 2014
- Antibody-drug Conjugates in The Management of Advanced Urothelial Carcinoma. Canadian Oncology Today.
- Can incomplete metastasectomy impact renal cell carcinoma outcomes? A propensity score matching analysis from a prospective multicenter collaboration. Société Internationale d’Urologie Journal. 2:82-95.